TY - JOUR
T1 - Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer
AU - Amato, Robert J.
AU - Perez, Cherie
AU - Pagliaro, Lance
PY - 2002/11
Y1 - 2002/11
N2 - Irofulven (6-Hydroxymethylacylfulvene, MGI-114) is the first of a new class of anticancer compounds the acylfulvenes which are derived from the natural product, illudin S. Irofulven is a potent anticancer agent with activity against a broad range of human tumors in vitro and in vivo. Irofulven covalently binds to DNA, inhibits DNA synthesis and induces apoptosis. Clinical activity has been observed in phase I studies. Because disease stabilizations were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of irofulven in this patient population. Twenty patients were accrued. Irofulven (11 milligrams per meter squared per day) was administered as a 5 minute intravenous infusion for 5 consecutive days, and response was evaluated every 8 weeks. There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer.
AB - Irofulven (6-Hydroxymethylacylfulvene, MGI-114) is the first of a new class of anticancer compounds the acylfulvenes which are derived from the natural product, illudin S. Irofulven is a potent anticancer agent with activity against a broad range of human tumors in vitro and in vivo. Irofulven covalently binds to DNA, inhibits DNA synthesis and induces apoptosis. Clinical activity has been observed in phase I studies. Because disease stabilizations were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of irofulven in this patient population. Twenty patients were accrued. Irofulven (11 milligrams per meter squared per day) was administered as a 5 minute intravenous infusion for 5 consecutive days, and response was evaluated every 8 weeks. There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer.
KW - Irofulven
KW - Kidney cancer
KW - Phase II
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0036830077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036830077&partnerID=8YFLogxK
U2 - 10.1023/A:1020649827173
DO - 10.1023/A:1020649827173
M3 - Article
C2 - 12448659
AN - SCOPUS:0036830077
SN - 0167-6997
VL - 20
SP - 413
EP - 417
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 4
ER -